Press release from GENE Online by Bernice Lottering
2024-11-26
PuriBlood Expands into Brazil on 11/25 with Clinical and Sales Agreement Signing
PuriBlood (TPEX: 6847), a Taiwanese biotech company, specializes in developing and producing Taiwan’s only domestic leukocyte filter blood bags. It officially signed two cooperation agreements with the Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH) and Cromo Comercio and Distribuicao de Materiais Odonto-Medico Hospitlares Ltda. (Cromo). Guests from the Taiwan External Trade Development Council (TAITRA) and others witnessed the agreements. This marks PuriBlood’s official entry into Brazil, the largest blood market in South America. It also sets a new milestone for Taiwanese medical and blood research technology in the country.
PuriBlood signs clinical and sales agreements with Brazil’s ABHH Association and Cromo Company, marking its entry into the largest blood market in Central and South America. Pictured (from left to right): ABHH Chairman Dante Langhi, PuriBlood Chairman Chen Yan-Wen, and Cromo Company Chairman Shi Mingqi (石明啟). Image courtesy of PuriBlood.
PuriBlood’s Innovations: Real-Time Leukocyte Reduction and High Platelet Recovery for Advanced Blood Processing
PuriBlood’s Chairman, Chen Yan-Wen, announced that Brazil is the first major single-market that PuriBlood has entered globally, with demand surpassing that of Taiwan. Brazil serves not only as a key gateway to Central and South America, but also provides a clinical and medical system modeled after the American system. Consequently, this will lay the groundwork for PuriBlood’s future entry into the European and American markets. Through Cromo, the company plans to expand its product sales to blood bank groups like the Pulsa group and large hospitals.
Additionally, in the newly signed agreement, ABHH will collaborate with PuriBlood to conduct clinical research on the Real-Time Leukocyte Reduction Filter and High Platelet Recovery Whole Blood Filter. ABHH Chairman Dante Langhi emphasized that all existing leukocyte reduction products in the market focus on blood storage at blood banks. However, PuriBlood’s Real-Time System, designed to simultaneously reduce leukocytes during blood donation, revolutionizes traditional processes. ABHH is proud to partner with PuriBlood during the clinical trial phase, aiming to create a new future.
PuriBlood Enters the Largest Blood Market in Central and South America, Signing Clinical and Sales Agreements with Brazil’s ABHH Association and Cromo Company
Cromo Company Chairman, Shi Mingqi (石明啟), highlighted that Taiwan’s blood donation rate ranks among the top globally at 8%. Taiwan produces approximately 1.8 million blood bags annually. In contrast, Brazil’s market produces 5 to 6 million blood bags per year. With policy promotion, Brazil’s market shows potential for growth. Shi believes that PuriBlood’s leukocyte reduction filter, with its superior performance, will deliver impressive results in Brazil.
The ABHH association includes over 4,000 members. It is a national federation of professionals in hematology, hemotherapy, and cell therapy. ABHH promotes cell and gene therapies, including CAR-T therapies for blood cancers. Furthermore, it collaborates with Brazil’s National Health Regulatory Agency (Anvisa) to regulate the development of cell therapies and ensure that new technologies can be applied in clinical settings.
Cromo, based in São Paulo, specializes in distributing medical, dental, and healthcare equipment. It supplies hospitals, laboratories, and surgical operations with necessary instruments and materials.